Safety study on the simultaneous administration of oral pentavalent recombinant rotavirus attenuated live vaccine and other vaccines in Chaoyang District, Beijing City from 2019 to 2021
10.3760/cma.j.cn112150-20241129-00956
- VernacularTitle:2019—2021年北京市朝阳区口服五价重配轮状病毒减毒活疫苗与其他疫苗同时接种后疑似预防接种不良反应分析
- Author:
Tianjing CHEN
1
;
Jiao ZHANG
1
;
Shuping LI
1
;
Li LI
1
;
Bin JIA
1
;
Jianxin MA
1
;
Zheng ZHANG
1
;
Jinbo HE
1
;
Yunhua BAI
1
Author Information
1. 北京市朝阳区疾病预防控制中心，北京100021
- Publication Type:Journal Article
- Keywords:
Pentavalent Inactivated Bovine Viral Diarrhea Vaccine;
Separate Inoculation;
Combined Vaccination;
SAFETY Surveillance
- From:
Chinese Journal of Preventive Medicine
2025;59(6):942-945
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of suspected adverse events following immunization (AEFI) after single administration of pentavalent recombinant rotavirus attenuated live vaccine (RV5) in Chaoyang District, Beijing City from 2019 to 2021 was 362.3 per 100 000 doses. The incidence rate of AEFI after simultaneous administration with oral polio vaccine (OPV), inactivated polio vaccine (IPV), hepatitis B vaccine (HBV), Haemophilus influenzae type b (Hib), and pneumococcal conjugate vaccine 13-valent (PCV13) was 239.3 per 100 000, 643.4 per 100 000, 346.8 per 100 000, 438.1 per 100 000, and 434.0 per 100 000, respectively. The specific incidence rates for common AEFI symptoms such as fever, local allergic rash, irritability, and vomiting under different vaccination regimens were as follows: RV5 alone (fever: 88.3 per 100 000, rash: 9.1 per 100 000, irritability: 100.5 per 100 000, vomiting: 83.3 per 100 000), RV5 and IPV simultaneous administration (fever: 239.4 per 100 000, rash: 104.7 per 100 000, irritability: 134.7 per 100 000, vomiting: 89.8 per 100 000), RV5 and OPV simultaneous administration (fever: 119.6 per 100 000, rash: 32.6 per 100 000, irritability: 32.6 per 100 000, vomiting: 32.6 per 100 000), RV5 and HBV simultaneous administration (fever: 111.0 per 100 000, rash: 69.4 per 100 000, irritability: 83.2 per 100 000, vomiting: 41.6 per 100 000), RV5 and Hib simultaneous administration (fever: 159.3 per 100 000, rash: 238.9 per 100 000, irritability: 0 per 100 000, vomiting: 39.8 per 100 000), and RV5 and PCV13 simultaneous administration (fever: 142.8 per 100 000, rash: 98.0 per 100 000, irritability: 126.0 per 100 000, vomiting: 25.2 per 100 000).
